[{"indications": "Indications\u00a0in combination with other drugs, tuberculosis resistant to first-line\r\ndrugs", "name": "CAPREOMYCIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.9 Antituberculosis drugs", "CAPREOMYCIN"], "cautions": "Cautions\u00a0auditory impairment; monitor renal, hepatic, auditory, and vestibular function\r\nand electrolytes; interactions: Appendix\r\n1 (capreomycin)", "side-effects": "Side-effects\u00a0hypersensitivity reactions including urticaria\r\nand rashes; leucocytosis or leucopenia, rarely thrombocytopenia; changes\r\nin liver function tests; nephrotoxicity, electrolyte disturbances;\r\nhearing loss with tinnitus and vertigo; neuromuscular block after\r\nlarge doses, pain and induration at injection site", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/204182.htm", "doses": ["By deep intramuscular injection, 1\u00a0g daily\r\n(not more than 20\u00a0mg/kg) for 2\u20134 months, then 1\u00a0g 2\u20133 times each week"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk\u2014teratogenic in animal studies"}]